Visugromab in Cachexia International Trial
ConditionCancer-associated Cachexia
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorCatalYm GmbH
About this trial
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:
* Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug).
Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Eligibility criteria
Qualifiers
Weight loss
Advanced cancer
Disqualifiers
Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
Trial design
Treatments tested in this trial
- Visugromab (CTL-002)
- Placebo
- Visugromab (CTL-002)
- Visugromab (CTL-002)
Treatment groups
518 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov